Sirolimus - Veloxis Pharmaceuticals

Drug Profile

Sirolimus - Veloxis Pharmaceuticals

Alternative Names: LCP-Siro

Latest Information Update: 12 Mar 2013

Price : $50

At a glance

  • Originator LifeCycle Pharma
  • Developer Veloxis Pharmaceuticals
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Transplant rejection

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Jun 2011 Sirolimus - LifeCycle Pharma is still available for licensing (http://www.lifecyclepharma.com/)
  • 29 Nov 2007 Phase-I clinical trials in Autoimmune disorders in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top